Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11661901 | 0.81 | ACHE (0.32) | — | |
| SCHEMBL11850956 | 0.79 | — | — | |
| SCHEMBL11661015 | 0.77 | KCNE1 (0.32) | — | |
| SCHEMBL11853875 | 0.69 | POLB (0.33) | — | |
| SCHEMBL1452157 | 0.66 | KDM1A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL1452653 | 0.66 | KDM1A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL11806271 | 0.66 | GAA (0.32) | — | |
| SCHEMBL11857719 | 0.66 | MEN1 (0.31) | — | |
| SCHEMBL11664241 | 0.65 | ACHE (0.32) | — | |
| SCHEMBL11658164 | 0.65 | ACHE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435962-A4 | TREATMENT OF TYPE I DIABETES | CELL PATHWAYS INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20060252762-A1 | Methods for treatment of multiple sclerosis | WHITEHEAD CLARK M | 2006-11-09 | — | — | US | disclosed |
| US-20060100210-A1 | Methods for treatment of scleroderma | WHITEHEAD CLARK M | 2006-05-11 | — | — | US | disclosed |
| US-6906064-B2 | Method for treating a patient with neoplasia using Iressa | OSI PHARMACEUTICALS, INC. | 2005-06-14 | — | — | US | disclosed |
| EP-1435961-A4 | TREATMENT FOR LUPUS ERYTHEMATOSUS | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435940-A4 | TREATMENT OF SCLERODERMA | CELL PATHWAYS INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1435962-A2 | TREATMENT OF TYPE I DIABETES | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435782-A1 | TREATMENT FOR CYSTIC FIBROSIS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435961-A2 | TREATMENT FOR LUPUS ERYTHEMATOSUS | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1435940-A1 | TREATMENT OF SCLERODERMA | Cell Pathways, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030009033-A1 | Substituted condensation products of N-benzyl-3-indenylacent amides with heterocyclic aldehydes for neoplasia | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6479493-B1 | INHIBITING PHOSPHODIESTERASE 2 IN THE DISEASED TISSUE, WITHOUT SUBSTANTIALLY INHIBITING CYCLOOXYGENASES I AND II, THEREBY CAUSING MACROPHAGE APOPTOSIS | CELL PATHWAYS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465494-B1 | PHOSPHODIESTERASE 2 AND 5 INHIBITORS; DOES NOT SUBSTANTIALLY INHIBIT COX I OR II; INDUCING APOPTOSIS IN PULMONARY MACROPHAGES THAT GENERATE LUNG DAMAGING METABOLITES AND LEUKOTRIENE B4 | CELL PATHWAYS, INC. | 2002-10-15 | — | — | US | disclosed |
| WO-2002067936-A1 | METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELL PATHWAYS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6426349-B1 | ADMINISTERING (Z)-5-FLUORO-2-METHYL-(4-PYRIDYLIDENE)-3-(N-BENZYL) INDENYLACETAMIDE HYDROCHLORIDE; REGULATING APOPTOSIS | CELL PATHWAY AND THE UNIVERSITY OF ARIZONA | 2002-07-30 | — | — | US | disclosed |
| US-6166053-A | Substituted condensation products of N-benzyl-3-idenylacetamides with heterocyclic aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1044187-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | OSI Pharmaceuticals, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-6066634-A | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5948779-A | APOPTOSIS; ANTICANCER AGENT | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999031065-A1 | N-BENZYL-3-INDENYLACETAMIDES DERIVATIVES FOR TREATING NEOPLASIA | CELL PATHWAYS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009033-A1 | Substituted condensation products of N-benzyl-3-indenylacent amides with heterocyclic aldehydes for neoplasia | ACIN1, AOX1, CCAR2 | HTR2A 3503/4885HTR2C 3046/4885SLC6A4 4266/4885 |
| US-20060100210-A1 | Methods for treatment of scleroderma | SSB, TST, ETF1 | HTR2A 4160/4885HTR2C 4067/4885SLC6A4 3878/4885 |
| US-20060252762-A1 | Methods for treatment of multiple sclerosis | MYT1, PMP22, OTC | HTR2A 3963/4885HTR2C 3751/4885SLC6A4 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.